GSK Student Wins NCI Award to Pursue Innovative Prostate Cancer Research

By Esther Napolitano,

Friday, November 17, 2017

Zeda Zhang
Summary

Zeda Zhang was recently honored with an award from the NCI for his work addressing drug resistance in prostate cancer care.

Zeda Zhang was recently awarded the Predoctoral to Postdoctoral Fellow Transition Award from the National Cancer Institute (NCI). The nationally competitive grant celebrates outstanding graduate students who have shown exceptional potential and interest in pursuing careers as independent cancer researchers.

A fifth-year PhD candidate at Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), Mr. Zhang was one of only 27 students in the United States to receive the fellowship this year.

“This is a competitive award in which PhD-granting institutions are allowed to nominate just one student,” says GSK Dean Kenneth Marians. “We’re very proud of Zeda and are excited about his future as a cancer researcher. The ability of a school as small as GSK to compete successfully on a national scale reflects the outstanding quality of our students and the strength of our curriculum.”

Mr. Zhang is the second GSK student to receive the prestigious award, which was introduced in 2016. The fellowship provides an NIH-level stipend and institutional allowance to support Mr. Zhang’s ongoing dissertation research at GSK and, upon earning his PhD, to facilitate his transition into the next stage of his career: a mentored, cancer-focused postdoctoral research position.

Taking on Drug Resistance

Mr. Zhang’s thesis research tackles the problem of drug resistance — a major challenge in cancer care. This has been a particular issue with antiandrogen therapies that target the androgen receptor in men with prostate cancer. Many men whose cancers initially respond well to these targeted therapies eventually die of relapsed, drug-resistant disease.

Recent studies have demonstrated that molecular signal disruptions between a tumor and its microenvironment can contribute to malignancy and resistance to therapy. Mr. Zhang is investigating the role of cancer-associated fibroblasts (cells that reside in the tumor microenvironment) in promoting prostate tumor growth and mediating drug resistance.

I have learned how to reconcile useful clinical observations, translate them into scientific hypotheses, and design disease-relevant research that bridges the gap from bench to bedside.
Zeda Zhang
Zeda Zhang GSK graduate student
Back to top

Making the Most of a Mentor’s Support

Integral to Mr. Zhang’s work is the use of new mouse model systems developed in the lab of his GSK thesis mentor, Charles Sawyers, MD, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. An internationally recognized physician-scientist, Dr. Sawyers is a Howard Hughes Medical Institute investigator whose research focuses on cancer drug resistance with an eye toward developing novel therapies.

“My work has benefited greatly from Dr. Sawyers’s scientific insight, guidance, and experience, as well as the collaborative research environment he fosters,” says Mr. Zhang. “I have learned how to reconcile useful clinical observations, translate them into scientific hypotheses, and design disease-relevant research that bridges the gap from bench to bedside.”

Back to top

Looking Ahead

After he graduates from GSK, Mr. Zhang plans to continue his training as a postdoctoral cancer researcher focused on exploring the molecular mechanisms of cancer progression and drug resistance. “By grasping a better understanding of the alterations in the cross talk between tumor cells and their surrounding components, I hope to discover new approaches to overcoming those problems,” explains Mr. Zhang.

He says that GSK has given him a solid foundation as a future independent investigator. “Although I am doing basic lab research, I have a very clear idea about the potential clinical impact of my work,” notes Mr. Zhang. “Being able to answer difficult scientific questions and help patients at the same time is what drives me to undertake this challenging but ultimately rewarding career.”

Back to top

Tags

Comments

Congratulate! Drug resistance of CRPC is the bottleneck of clinical treatment and a very important translational research direction. I come from China Academy of Chinese Medicine Science.I have a lot of patients with prostate cancer in the clinic.I hope your research will help improve the efficacy of prostate cancer.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.